Matthias Stelljes

1 week ago | nature.com | Arnon Nagler |Nicolaus Kröger |Matthias Stelljes |Johan Maertens |Gesine Bug |Didier Blaise | +3 more

AbstractThe cytogenetic risk category retains a pivotal role in the prediction of prognosis in acute myeloid leukemia (AML) patients undergoing hematopoietic stem cell transplantation (HSCT), however, its impact on secondary AML (sAML) is less established. We assessed whether the ELN 2022 cytogenetic risk score predicts outcomes in sAML patients in remission undergoing HSCT from HLA-matched donors performed between 2010 and 2022.

Sep 8, 2024 | oncodaily.com | Matthias Stelljes

Yan Leyfman:“Had an incredible time attending my first Society of Hematologic Oncology meeting and presenting our research! Grateful to SOHO for an enriching experience and the chance to connect with some of the brightest stars in oncology.

Dec 18, 2023 | emjreviews.com | Emily Curran |Matthias Stelljes

INTRODUCTIONThe prognosis for adult patients with R/R B-cell ALL can be poor, and treatment can be challenging. The goal of treatment is to achieve remission and control the disease, as well as manage associated symptoms and improve a patient’s quality of life.

Sep 11, 2023 | ashpublications.org | Matthias Stelljes

Immunotherapy shows promise in treating hematological malignancies by harnessing the immune system's ability to target and kill cancer cells selectively. Unlike traditional chemotherapy and radiation therapy, which damage cells unspecifically, immunotherapies offer more targeted approaches.